Market Cap 4.60B
Revenue (ttm) 516.68M
Net Income (ttm) 32.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 28.97
Profit Margin 6.37%
Debt to Equity Ratio 1.00
Volume 55,300
Avg Vol 45,312
Day's Range N/A - N/A
Shares Out 338.40M
Stochastic %K 4%
Beta N/A
Analysts Strong Sell
Price Target $23.33

Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9093 3855
Address:
55 Flemington Road, Level 4, North Melbourne, Australia
Latest News on TLX
Telix H1 2025 Results: Investor Webcast Notification

Jul 29, 2025, 6:58 PM EDT - 3 days ago

Telix H1 2025 Results: Investor Webcast Notification


Telix Reports $204M Revenue, Up 63% YOY

Jul 22, 2025, 4:06 AM EDT - 11 days ago

Telix Reports $204M Revenue, Up 63% YOY


Gozellix Receives Permanent HCPCS Code

Jul 9, 2025, 6:45 PM EDT - 23 days ago

Gozellix Receives Permanent HCPCS Code


Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Apr 28, 2025, 6:30 PM EDT - 3 months ago

Telix's Illuccix PSMA-PET Imaging Agent Approved in France


Telix Reports US$186M Q1 Revenue, Up 62% YOY

Apr 22, 2025, 4:17 AM EDT - 3 months ago

Telix Reports US$186M Q1 Revenue, Up 62% YOY


Telix Appoints Paul Schaffer as Chief Technology Officer

Apr 7, 2025, 6:30 AM EDT - 4 months ago

Telix Appoints Paul Schaffer as Chief Technology Officer


Telix Pharmaceuticals: Building A Radiopharma Powerhouse

Apr 5, 2025, 1:03 AM EDT - 4 months ago

Telix Pharmaceuticals: Building A Radiopharma Powerhouse


Anne Whitaker Appointed as Non-Executive Director

Apr 3, 2025, 6:13 PM EDT - 4 months ago

Anne Whitaker Appointed as Non-Executive Director


FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Mar 21, 2025, 6:30 AM EDT - 4 months ago

FDA Approves New Prostate Cancer Imaging Agent Gozellix®


Telix Adds Lead-212 Isotope Production Capability

Mar 12, 2025, 6:41 PM EDT - 5 months ago

Telix Adds Lead-212 Isotope Production Capability


Illuccix® Approved in the United Kingdom

Feb 12, 2025, 4:38 PM EST - 6 months ago

Illuccix® Approved in the United Kingdom


Telix Completes Acquisition of RLS (USA) Inc.

Jan 27, 2025, 4:43 PM EST - 6 months ago

Telix Completes Acquisition of RLS (USA) Inc.


Illuccix® Receives European Approval

Jan 16, 2025, 5:06 PM EST - 7 months ago

Illuccix® Receives European Approval


Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Jan 13, 2025, 2:08 AM EST - 7 months ago

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue